

# Effect-site targeted propofol for anaesthesia in children

<b>Submission date</b> 23/08/2010	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 22/02/2011	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 09/05/2017	<b>Condition category</b> Surgery	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Neil Morton

**Contact details**  
Royal Hospital for Sick Children  
Dalnair Street  
Glasgow  
United Kingdom  
G3 8SJ

## Additional identifiers

**Clinical Trials Information System (CTIS)**  
2009-014568-21

**Protocol serial number**  
EudraCT number: 2009-014568-21

## Study information

**Scientific Title**  
A multicentre open study of the performance of an effect-site targeted infusion of propofol used for induction and maintenance of anaesthesia in children under 16 years

## **Study objectives**

The equilibration of propofol from the plasma compartment to brain can be described using the time to peak effect and keo values for propofol. This is an open study to determine the performance of an effect-site targeted infusion based on the age-dependent values described by Jeleazcov (2008), using the four standard measures of bias, precision, divergence and wobble. These derived parameters estimate quantitatively whether the system over- or under-delivers propofol and how this varies both between patients and for an individual patient over time.

## **Ethics approval required**

Old ethics approval format

## **Ethics approval(s)**

Not provided at time of registration

## **Study design**

Multicentre open non-randomised non-controlled study

## **Primary study design**

Interventional

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

General anaesthesia

## **Interventions**

Patients will be recruited from suitable operating lists and after appropriate consent, will undergo induction and maintenance of general anaesthesia using the effect-site targeted infusion of propofol. Patients will have an intravenous (iv) cannula inserted through topically-anaesthetised skin and a bolus of remifentanyl 0.5 µg/kg and lignocaine 0.2 mg/kg will be injected to reduce propofol pain at induction. Bispectral index monitoring will be used to monitor depth of anaesthesia throughout the induction and maintenance period.

During the period of maintenance of anaesthesia, the target effect-site concentration will be lowered and a hysteresis loop of depth of anaesthesia against propofol concentration will be populated using the BIS data and plasma samples collected from a second venous cannula. From this, an estimate of the keo value for propofol can be calculated. The period of lightening of anaesthesia may be terminated at any point because of clinical or BIS-derived suspicions of a requirement for greater depth of anaesthesia. The main outcome measure of the performance of the infusion algorithm is calculated from propofol sampling performed during the remainder of the period of anaesthesia using non-linear mixed effects monitoring. A maximum of 5 ml blood will be sampled from each patient.

The involvement of each participant concludes at the time of emergence from anaesthesia.

## **Intervention Type**

Drug

## **Phase**

Phase IV

**Drug/device/biological/vaccine name(s)**

Propofol

**Primary outcome(s)**

Performance of an effect-site target controlled infusion (TCI) pharmacokinetic model for children aged 1 to 12 years and weight 6 - 60 kg, as calculated from the four standard parameters described by Varvel et al. The performance error (PE) is calculated from the concentration of propofol measured in whole blood (C<sub>meas</sub>) and the concentration predicted by the software (C<sub>pred</sub>) as follows:  $PE(\%) = ((C_{meas} - C_{pred}) / C_{pred}) \times 100$ . Four standard measures of performance are derived from this value, namely bias, precision, divergence and wobble. These derived parameters estimate quantitatively whether the system over- or under-delivers propofol, and how this varies both between patients and for an individual patient over time.

**Key secondary outcome(s)**

1. Population pharmacokinetics of propofol in children aged 1 to 12 years using non-linear effects modelling (NONMEM). This allows the calculation of volume of distribution and clearance of propofol and potential relationships between these pharmacokinetic parameters and the variables of age, gender and weight to be explored.
2. Pharmacodynamic modelling, using bispectral index as a measure of depth of anaesthesia. This will allow direct estimation of the blood-brain equilibration rate-constant (ke<sub>0</sub>) for propofol in this patient population.
3. Establish a safety profile for effect-site TCI propofol based on the pharmacodynamics of Jeleazcov et al by identifying the rate of adverse events associated with the use of effect-site targeted propofol infusion

**Completion date**

30/11/2011

**Eligibility****Key inclusion criteria**

1. American Society of Anaesthesiologists (ASA) grade 1 and 2 healthy male and female children aged 1 to 12 years (inclusive)
2. Weight 6 - 60 kg
3. Elective surgery requiring general anaesthesia
4. Surgery or procedure of expected duration of at least 30 minutes
5. Written parental consent or child's consent if competent, for inclusion
6. Child appropriate for intravenous induction and maintenance of anaesthesia with propofol
7. Agreement to undergo intravenous induction of anaesthesia
8. No contraindication to application of topical local anaesthesia prior to cannulation

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Child

**Lower age limit**

1 years

**Upper age limit**

12 years

**Sex**

All

**Key exclusion criteria**

1. Parental refusal or refusal of child if competent
2. Allergy to propofol or any constituent of propofol
3. Sensitivity to adhesive agents, as used in the Bispectral Index (BIS) measurement strip
4. Refusal of intravenous induction
5. Need for sedative premedication
6. Inadequate topical analgesia for intravenous cannulation
7. Inability to site intravenous cannula within two attempts

**Date of first enrolment**

01/12/2010

**Date of final enrolment**

30/11/2011

**Locations****Countries of recruitment**

United Kingdom

Scotland

**Study participating centre**

Royal Hospital for Sick Children

Glasgow

United Kingdom

G3 8SJ

**Sponsor information****Organisation**

NHS Greater Glasgow and Clyde (UK)

**ROR**

<https://ror.org/05kdz4d87>

# Funder(s)

## Funder type

Research organisation

## Funder Name

National Institute of Academic Anaesthesia (NIAA) (UK)

## Funder Name

Yorkhill Children's Foundation (UK)

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes